Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of the American Medical Association (JAMA)

• Publication date

  2004-10-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/JAMA.292.16.1955PMID 15507580
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Community-acquired pneumonia.

  2013cited by this paper
• Effect of nizatidine 300 mg at night and omeprazole 20 mg in the morning on 24-hour intragastric pH and bacterial overgrowth in patients with acute duodenal ulcer

  2005cited by this paper
• Gastric acid‐suppressive therapy and community‐acquired respiratory infections

  2003cited by this paper
• Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity*

  2002cited by this paper
• Detection of type B influenza virus genes from biopsied gastric mucosa

  2002cited by this paper
• Initial management strategies for dyspepsia.

  2001cited by this paper
• Hospitalization with respiratory disease following hiatal hernia and reflux esophagitis in a prospective, population-based study.

  2001cited by this paper
• Consultations and referrals for dyspepsia in general practice—a one year database survey

  2001cited by this paper
• Non‐Helicobacter pylori bacterial flora during acid‐suppressive therapy: differential findings in gastric juice and gastric mucosa

  2001cited by this paper
• Risk Factors for Esophageal Candidiasis

  2000cited by this paper
• Postmarketing Surveillance Based on Electronic Patient Records: The IPCI Project

  1999cited by this paper
• The effects of cimetidine, ranitidine, and famotidine on human neutrophil functions.

  1999cited by this paper
• Community-acquired pneumonia

  1998cited by this paper
• Effect of nizatidine 300 mg at night and omeprazole 20 mg in the morning on 24-hour intragastric pH and bacterial overgrowth in patients with acute duodenal ulcer

  1996cited by this paper
• Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study.

  1996cited by this paper
• Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis.

  1996cited by this paper
• Activity Inhibition of Cytolytic Lymphocytes by Omeprazole

  1996cited by this paper
• The effect of omeprazole on human natural killer cell activity.

  1995cited by this paper
• Gastroduodenal dysfunction and bacterial colonisation of the ventilated lung.

  1993cited by this paper
• The Introduction of Computer-based Patient Records in the Netherlands

  1993cited by this paper
• International primary care classifications: the effect of fifteen years of evolution.

  1992cited by this paper
• Role of gastric colonization in the development of pneumonia in critically ill trauma patients: results of a prospective randomized trial.

  1990cited by this paper
• Potent acid reduction and risk of enteric infection.

  1990cited by this paper
• Prevalence of symptoms of dyspepsia in the community.

  1989cited by this paper
• Relationship between gastric secretion and infection.

  1987cited by this paper
• Effect of cimetidine on the gastric bacterial flora.

  1980cited by this paper
• Influence of gastric acidity on bacterial and parasitic enteric infections. A perspective.

  1973cited by this paper
• THE CLINICAL IMPORTANCE OF ACHLORHYDRIA *

  1934cited by this paper

• Impact of proton pump inhibitor use on immune-related adverse events in patients with non-small cell lung cancer: a retrospective study

  2026cites this paper
• Association of Pneumonia, Fracture, Metabolic, and Renal Events With Long‐Term Proton Pump Inhibitor Use in Patients With Chronic Kidney Disease

  2025influential citation
• Good clinical practice recommendations for proton pump inhibitor prescription and deprescription. A review by experts from the AMG.

  2025cites this paper
• AGA Clinical Practice Guideline on Surveillance of Barrett's Esophagus.

  2025cites this paper
• Association between preoperative proton pump inhibitor use and postoperative infectious and renal complications following major elective surgery

  2025influential citation
• Ilaprazole: Distinctive Pharmacokinetic and Pharmacodynamic Properties Among Proton Pump Inhibitors

  2025cites this paper
• Effect of Proton Pump Inhibitors in Patients Undergoing Percutaneous Coronary Intervention With Aspirin-Free Strategy

  2025cites this paper
• Evidence for acid‐sensing ion channel 3 (ASIC3) involvement in cough resulting from aspiration of gastric fluid

  2025cites this paper
• Computational design and cheminformatics profiling of omeprazole derivatives for enhanced proton pump inhibition of potassium-transporting ATPase alpha chain 1

  2025cites this paper
• Clinical, Bacteriological And Radiological Profile Of Patients With Community Acquired Pneumonia In A Tertiary Care Hospital In South India

  2025cites this paper
• Analysis of infection-related adverse events induced by proton pump inhibitors based on the FAERS and JADER databases

  2025cites this paper
• Chemoprevention in Barrett's Esophagus: An Updated Review.

  2025cites this paper
• Recomendaciones de buena práctica clínica en la prescripción y deprescripción de inhibidores de la bomba de protones. Revisión por expertos de la AMG

  2025cites this paper
• A meta-analysis of the effects of proton pump inhibitors on the risk of gastric cancer

  2025cites this paper
• Impact of concomitant use of proton pump inhibitors or cardiovascular medication on survival outcomes of patients with metastatic renal cell carcinoma treated with nivolumab

  2025cites this paper
• Bronchopulmonary dysplasia, pulmonary hypertension, and neonatal gastroesophageal reflux: Association, causation, or neither?

  2025cites this paper
• Multidrug-resistant Klebsiella pneumoniae coinfection with multiple microbes: a retrospective study on its risk factors and clinical outcomes

  2025cites this paper
• Adverse Events Associated With Proton Pump Inhibitors: Fact vs Fiction.

  2024cites this paper
• American Society for Gastrointestinal Endoscopy guideline on the diagnosis and management of GERD: methodology and review of evidence

  2024cites this paper
• Proton pump inhibitors associated with severe COVID‐19 among two‐dose but not three‐dose vaccine recipients

  2024cites this paper
• Exploring and understanding adverse effect of Proton Pump Inhibitors

  2024cites this paper
• American Society for Gastrointestinal Endoscopy guideline on the diagnosis and management of GERD: summary and recommendations.

  2024cites this paper
• Good clinical practice recommendations for the diagnosis and treatment of gastroesophageal reflux disease. An expert review from the Asociación Mexicana de Gastroenterología.

  2024cites this paper
• Proton pump inhibitors and risk of severe COVID-19 in older people.

  2024cites this paper
• Different Outcome in COVID-19 Patients with or without PPI Use: A Systematic Review and Meta-analysis

  2024cites this paper
• Awareness of Proton Pump Inhibitor Adverse Events and Treatment Pattern Change According to Physician Practice: A National Questionnaire Study in Korea

  2024cites this paper
• Evaluation of Appropriate Use of Proton Pump Inhibitors in Non-critically Ill Patients in Tertiary Medical Center: A Retrospective Study.

  2024cites this paper
• Recomendaciones de buena práctica clínica en el diagnóstico y tratamiento de la enfermedad por reflujo gastroesofágico. Revisión por expertos de la Asociación Mexicana de Gastroenterología

  2024cites this paper
• Factors Associated with Hospitalized Community-Acquired Pneumonia among Elderly Patients Receiving Home-Based Care

  2024cites this paper
• Acute COPD exacerbations and in-hospital treatment-related problems: An observational study

  2024cites this paper
• Association of acid-suppressive therapy and tuberculosis: A causal or coincidental link to the infection?

  2024cites this paper
• Long-Term Effects of Proton Pump Inhibitors in Patients Undergoing Percutaneous Coronary Intervention in High-Risk Subgroups.

  2024cites this paper
• Emerging Long-Term Risks of the Use of Proton Pump Inhibitors and Potassium-Competitive Acid Blockers.

  2024cites this paper
• Impact of acid blocker therapy on growth, gut microbiome, and lung disease in young children with cystic fibrosis

  2024cites this paper
• Bacteria in cancer initiation, promotion and progression

  2023cites this paper
• Proton Pump Inhibitors Usage Among Discharged Patients in a Tertiary Care Hospital- An Observational Study

  2023cites this paper
• Evolution of proton pump inhibitor prescribing from 2017 to 2021 at 14 secondary and tertiary hospitals in China：a multicentre cross-sectional study

  2023cites this paper
• The effect of concomitant proton pump inhibitor use on survival outcomes of Nivolumab-treated renal cell carcinoma patients: a multicenter study

  2023cites this paper
• Long-Term Proton Pump Inhibitor Therapy Increases the Risk of Infection in Patients with Incident Hemodialysis

  2023cites this paper
• Characterization of Eosinophilic Esophagitis in Infants and Toddlers

  2023cites this paper
• Risk of pneumonia associated with proton pump inhibitor use

  2023cites this paper
• Bolus alba mit und ohne Gentiana lutea versus Protonenpumpenhemmer-Therapie bei nichterosiver Gastritis – Eine retrospektive Analyse

  2023cites this paper
• Increased mortality in patients with hematologic malignancies treated with proton pump inhibitors: a nationwide cohort study

  2023cites this paper
• Cirrhotic patients on proton pump inhibitors are at a twofold risk of spontaneous bacterial peritonitis independently of gastrointestinal bleeding: a population-based retrospective study

  2023cites this paper
• Association between Gut Microbiota and SARS-CoV-2 Infection and Vaccine Immunogenicity

  2023cites this paper
• Diagnosis and minimally invasive management of erosive tooth wear

  2023cites this paper
• Association Between Proton Pump Inhibitor Use and Spontaneous Bacterial Peritonitis or Hepatic Encephalopathy in Cirrhotic Patients: A Systematic Review and Meta-analysis

  2023cites this paper
• Risk factors and outcome associated with coinfection with carbapenem-resistant Klebsiella pneumoniae and carbapenem-resistant Pseudomonas aeruginosa or Acinetobacter baumanii: a descriptive analysis

  2023cites this paper
• Gastroprotective therapy in patients with atrial fibrillation receiving anticoagulant therapy: A review

  2023cites this paper
• Effects of gastroesophageal reflux disease treatment with proton pump inhibitors on the risk of acute exacerbation and pneumonia in patients with COPD

  2023cites this paper
• Effect of 90 Days Sub-chronic Administration of Omeprazole (A Proton Pump Inhibitor) on Haematological, Biochemical, Antioxidant, Reproductive and Histopathological Parameters in Male and Female Rats

  2023cites this paper
• Assessing Frequency and Appropriateness of Proton Pump Inhibitor Deprescription in Patients Requiring Endoscopic Therapy for Esophageal Strictures

  2023cites this paper
• Association between Proton Pump Inhibitors Use and Spontaneous ‎Bacterial Peritonitis Development in Egyptian Cirrhotic Patients with Ascites‎

  2022cites this paper
• Risk of urinary stone formation associated to proton pump inhibitors: A systematic review and metanalysis.

  2022cites this paper
• Proton pump inhibitor usage associates with higher risk of first episodes of pneumonia and peritonitis in peritoneal dialysis patients

  2022cites this paper
• Gastroesophageal reflux disease increases susceptibility to non-tuberculous mycobacterial pulmonary disease.

  2022cites this paper
• Pre-existing Proton Pump Inhibitor Treatment and Short-Term Prognosis of Acute Myocardial Infarction Patients

  2022cites this paper
• Proton pump inhibitors are associated with reduced periodontal disease severity

  2022cites this paper
• Great escape: how infectious SARS-CoV-2 avoids inactivation by gastric acidity and intestinal bile

  2022cites this paper
• High vs Low Dose Proton Pump Inhibitor (PPI) related Mortality in Hospitalized Coronavirus Disease-19 (COVID-19): A Retrospective Cohort Study

  2022cites this paper
• Effects of prolonged proton pump inhibitor treatment on nutritional status and respiratory infection risk in cystic fibrosis: A matched cohort study.

  2022cites this paper
• Modifiable and non-modifiable risk factors for non-ventilator-associated hospital-acquired pneumonia (nvHAP) identified in a retrospective cohort study.

  2022cites this paper
• Knowledge of Egyptian faculty members about voice care: a national cross-sectional study

  2022cites this paper
• Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma

  2022cites this paper
• The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy among Patients with Urothelial Carcinoma: A Meta-Analysis

  2022cites this paper
• The Proton Pump Inhibitors Use and COVID-19 from Prior to Vaccination Perspective: A Review

  2022cites this paper
• The Use of Proton Pump Inhibitors and COVID-19: A Systematic Review and Meta-Analysis

  2022cites this paper
• Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis

  2022cites this paper
• AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.

  2022cites this paper
• The link between airway reflux and non-acid reflux in children: a review.

  2022cites this paper
• Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper

  2022cites this paper
• Acid suppression duration does not alter anastomotic stricture rates after esophageal atresia with distal tracheoesophageal fistula repair: A prospective multi-institutional cohort study.

  2022cites this paper
• Risk of Post-Myocardial Infarction Pneumonia with Proton Pump Inhibitors, H2 Receptor Antagonists and Mucoprotective Agents: A Retrospective Nationwide Cohort Study

  2022cites this paper
• To Thicken or Not to Thicken: Exploring the Use of Math-Based Clinical Decision Making

  2022cites this paper
• Incorporation of Student Pharmacists into a Proton Pump Inhibitor Deprescribing Telehealth Program for Rural Veterans

  2022cites this paper
• Pediatric prescriptions of proton pump inhibitors in France (2009-2019): a time-series analysis of trends and practice guidelines impact.

  2022cites this paper
• Stop of proton-pump inhibitor treatment in patients with liver cirrhosis (STOPPIT): study protocol for a prospective, multicentre, controlled, randomized, double-blind trial

  2022cites this paper
• Prophylactic acid suppressants in patients with primary neurologic injury: A systematic review and meta-analysis of randomized controlled trials.

  2022cites this paper
• Proton pump inhibitors may contribute to progression or development of chronic obstructive pulmonary disease—A sequence symmetry analysis approach

  2021cites this paper
• Dietary risk factors and therapy outcomes of swallowing-related problems in laryngopharyngeal reflux: patients’ perspectives

  2021cites this paper
• Proton Pump Inhibitors and the Risk of Community-Acquired Pneumonia: An Updated Meta-analysis

  2021cites this paper
• Should we routinely prescribe proton pump inhibitors peri-operatively in elderly patients with hip fractures? A review of the literature

  2021cites this paper
• Inhaled Corticosteroid (ICS) Use and Invasive Pneumococcal Pneumonia.

  2021cites this paper
• Proton-pump Inhibitors and the Risk of Dementia: A Systematic Review and Meta-analysis

  2021cites this paper
• Association of proton‐pump inhibitor use with adverse health outcomes: A systematic umbrella review of meta‐analyses of cohort studies and randomised controlled trials

  2021cites this paper
• Effect of an In Vitro Proximal Gastrointestinal Tract on Viability of Commercially Available Equine Probiotics.

  2021cites this paper
• Longitudinal Data Discontinuity in Electronic Health Records and Consequences for Medication Effectiveness Studies

  2021cites this paper
• Proton pump inhibitor use and appropriateness analysis: a snapshot from a secondary care hospital

  2021cites this paper
• Proton-Pump Inhibitor Use and Risk of Community-Acquired Pneumonia in Congenital Heart Disease Patients

  2021cites this paper
• Association of proton pump inhibitor use with the development of febrile neutropenia in lymphoma patients

  2021cites this paper
• Association between hospital-acquired pneumonia and proton pump inhibitor prophylaxis in patients treated with glucocorticoids: a retrospective cohort study based on 307,622 admissions in China

  2021cites this paper
• Side effects of long-term use of proton pump inhibitors: practical considerations.

  2021cites this paper
• Analysis of the Effect of Proton-Pump Inhibitors on the Course of COVID-19

  2021cites this paper
• Lansoprazole for persistent throat symptoms in secondary care: the TOPPITS RCT.

  2021cites this paper
• The efficacy and safety of acid suppressants for gastrointestinal bleeding prophylaxis in cardiac care unit patients

  2021cites this paper
• The risk of community-acquired pneumonia in children using gastric acid suppressants

  2021cites this paper
• Association of Chronic Acid Suppression and Social Determinants of Health with COVID-19 Infection

  2021cites this paper
• Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study

  2021cites this paper
• Proton pump inhibitors and risk of all‐cause and cause‐specific mortality: A cohort study

  2021cites this paper
• Does Long-Term Proton Pump Inhibitor Use Pump Up Your Risk of Adverse Effects?

  2021cites this paper